MOZOM-analyse

MOZOM compares: Sanofi EU antitrust investigation, flu vaccine marketing or medical guidance?

Europese Commissie, Brussels Times, Fierce Pharma en Reuters via Yahoo Finance Health 3 juli 2026 om 18:11

Type: Analyse Author: the MOZOM.nl editorial team Published: 3 juli 2026 om 18:11 Report a correction

AI image of a European vaccination clinic with elderly patients and anonymous flu vaccines illustrating the Sanofi EU antitrust investigation.

Source: Europese Commissie, Brussels Times, Fierce Pharma en Reuters via Yahoo Finance
MOZOM headline: MOZOM compares: Sanofi EU antitrust investigation, flu vaccine marketing or medical guidance?
Original headline: The European Commission opens an investigation into possible anti-competitive behavior by Sanofi regarding the promotion of flu vaccine for vulnerable patients
Author: the MOZOM.nl editorial team
Date: 3 juli 2026 om 18:11
Subject: The European Commission is investigating whether Sanofi violated EU competition rules with a communications campaign for the flu vaccine Efluelda and against CSL Seqirus' rival Fluad.

Summary of the original report

The European Commission has opened a formal competition investigation into Sanofi, the French pharmaceutical company that sells the enhanced flu vaccine Efluelda. According to the Commission, the investigation revolves around the question of whether Sanofi conducted a misleading communication campaign that portrayed the competing vaccine Fluad from CSL Seqirus as inferior. The campaign is said to have mainly targeted healthcare professionals in Germany and France and may have gone against national vaccination recommendations in several EU countries. The Commission emphasizes that opening an investigation is not a finding of guilt. Sanofi says, according to reports, that it is adhering to the rules and cooperating.

Own source research

MOZOM has placed the source layers next to each other. Layer one: the Commission explicitly says that the research affects Efluelda, Fluad, vulnerable patients and communication towards healthcare professionals in Germany and France. Layer two: the legal core is not whether Efluelda is medically useful, but whether Sanofi, as the dominant player, has wrongly portrayed a competing vaccine as inferior. Layer three: the procedure remains open; a formal investigation is not a conviction and Sanofi may respond or make commitments. MOZOM's own layer is that the file shows how subtle power can work in healthcare. Not only through price, patents or tenders, but also through sentences in presentations, scientific claims and the way guidelines are explained to doctors.

Striking in this message

It is striking that the word marketing can sound too light here. For regular consumer products, marketing is about preference and attention. With vaccines for vulnerable elderly people, the same marketing touches on trust in medical guidelines. If communications portrays a competitor as inferior, it can not only shift market share, but also change the choice environment for physicians and patients.

Less visible context

It is less visible that competition in healthcare is not just about lower prices. Competition can also protect against information that becomes too one-sided. If one company has a strong position in a specific medical market, its language takes on extra weight. For vulnerable patients, the question of power is therefore not abstract: who determines what information the doctor receives as reliable?

Possible message behind the news

One possible message is that sometimes power in healthcare doesn't shout. She is in which study is emphasized, which advice is left out and how a competitor in the consulting room is indirectly portrayed.

Neutral conclusion

The neutral conclusion: the European Commission is investigating Sanofi, but has not established guilt. The sharper MOZOM reading is that this research is bigger than one flu vaccine: it crosses the line between legitimate promotion and medical management in a market where vulnerable patients depend on reliable information. This is analysis, not medical advice.